Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 3/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17201635 | 0.73 | PIM1 (0.40) | DYRK1ADYRK2DYRK1BPIM1MAPT | |
| SCHEMBL16719595 | 0.71 | DYRK1A (0.34) | DYRK1ADYRK2DYRK1BMAPTIDO1 | |
| SCHEMBL7447711 | 0.68 | ALDH1A1 (0.38) | ALOX5APFEN1ADRA1AADRA1BADRA1D | |
| SCHEMBL7465327 | 0.66 | NPC1 (0.46) | MAPT | |
| SCHEMBL12853984 | 0.66 | ALOX5AP (0.50) | ALOX5APFEN1PIM1ADRA1AADRA1B | |
| SCHEMBL12853973 | 0.66 | ALOX5AP (0.50) | ALOX5APFEN1PIM1ADRA1AADRA1B | |
| SCHEMBL17701264 | 0.64 | PIM1 (0.40) | DYRK1ADYRK2DYRK1BPIM1MAPT | |
| SCHEMBL14994785 | 0.64 | DYRK1A (0.36) | DYRK1ADYRK2DYRK1BPIM1MAPT | |
| SCHEMBL2513836 | 0.63 | PIM1 (0.58) | DYRK1ADYRK2DYRK1BPIM1MAPT | |
| SCHEMBL4072793 | 0.63 | IDO1 (0.47) | ALOX5APFEN1PIM1ADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | claimed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | claimed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | claimed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | ALOX5AP 3723/4885FEN1 3185/4885DYRK1A 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.